Craig M. McDonald, MD, on Developing Gene Therapy for Different Populations of DMD
The principal investigator of the HOPE-2 trial discussed results of the trial in the non-ambulatory population of patients with Duchenne muscular dystrophy.
Richard Fessler, MD, on Evaluating Oligodendrocyte Cell Therapy for Spinal Cord Injury
The professor of neurosurgery at Rush University Medical School discussed data seen in the phase 1/2 clinical trial of LCTOPC1.
Pursuing Strategic Partnerships in Cell Therapy
Raphaël G. Ognar, chief executive officer and co-founder of NKILT Therapeutics, discussed approaches to help increase patient access to cell therapies.
Wolfgang Miesbach, MD, PhD, on Future Research with EtranaDez
The professor and head of coagulation disorders and Comprehensive Care Centre, University Hospital of Frankfurt, Germany, discussed future integration of EtranaDez into hemophilia B treatment.
Daniel Judge, MD, on Translational Gene Therapy for Cardiac Disorders
Genetics is the future of heart failure and cardiomyopathy treatment, Judge told CGTLive in an interview.
Stephanie Cherqui, PhD, on Bringing Attention to Cystinosis and Gene Therapy
The associate professor from UC San Diego discussed promising efficacy and safety data from a phase 1/2 trial.
Geoffrey Hodge on Developing CAR T-Cell Therapies for Solid Tumors
Geoffrey Hodge, chief executive officer of SOTIO Biotech US, discussed the company's development of the BOXR cell therapy platform.
James Beck, PhD, on Identifying Genetic Variants of Parkinson Disease
The chief scientific officer and senior vice president of the Parkinson’s Foundation discussed mutations the Parkinson’s Foundation has identified.
Susan Ruediger on Pursuing Gene Therapies for CMT
Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the foundation’s mission.
Barbara Lavery on Collaborating to Develop Cancer Therapies
The chief program officer of the Alliance for Cancer Gene Therapy discussed the work the nonprofit is doing.
Alba Gonzalez-Junca, PhD, on Logic-gated CAR-NK Cell Development
The associate director of Research at Senti Biosciences discussed the company's research on using logic-gated CAR-NK cells for the treatment of AML and solid tumors.
Gavin Macbeath, PhD, on Screening for Off-Target Effects
The chief scientific officer at TScan Therapeutics discussed the company’s SafetyScan technology.
Michael Leek, PhD, on Manufacturing Challenges in Cell Therapy
The co-founder and executive chairman of TC BioPharm discussed his thoughts on the regulatory, logistical, and quality hurdles of manufacturing cell therapies.
Serena De Vita, MD, PhD, on Speedy Manufacturing of PHE885 for Multiple Myeloma
The senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.
Jeffrey Miller, MD, on Improving NK Cells for Solid and Hematologic Malignancies
The professor of medicine and University of Minnesota Medical School discussed the advantages and unmet needs of natural killer cells in oncology.
Stefanie Bailey, PhD, on the Role of Interferon-γ in CAR T-Cell Therapy
The research fellow from Harvard Medical School discussed blocking IFNg as a potential approach to reduce toxicities.
Adham Bear, MD, On Immunotherapy Targeting Mutant KRAS
The instructor of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania discussed his thoughts on the potential of targeting mutant KRAS with immunotherapy.
Daniel Judge, MD, on Making Genetic Testing, Insights More Mainstream
MUSC recently launched In Your DNA SC, a 4-year study to collect and glean insights from genetic testing in the general population.
Jakob Dupont, MD, on ATA188’s Potential in All Forms of Multiple Sclerosis
The global head of research and development at Atara Biotherapeutics discussed ATA188 ahead of anticipated data readouts this month.
Mazyar Shadman, MD, MPH, on MB-106's Potential in Follicular Lymphoma
The associate professor at Fred Hutch Cancer Center discussed data presented at the EHA 2022 Congress.
Christian Hinrichs, MD, on Improving Solid Tumor Targeting With Engineered T-Cell Therapies
The chief of cancer immunotherapy at Rutgers Cancer Institute discussed clinical results with different cell therapy approaches.
Breanna DiAndreth, PhD, on Improving Selective Targeting of Tumor Cells
The scientist at A2 Biotherapeutics discussed the company’s dual-receptor Tmod technology.
Peter Bross, MD, on Regulating Cell Therapies: Lessons Learned
The acting chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed the evolution of cell therapies in the past decade.
Connecting Patient Advocacy and Industry for Gene Therapy Development
Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the panel discussion she participated in at BIO 2022.
Pursuing Slow but Steady Gene Therapy Development
Michael Parini, chief executive officer and director, Freeline Therapeutics, discussed the company’s pipeline and mission.
David Weinstein, MD, on Delivering Gene Therapy Directly to the Brain
The senior vice president of clinical development at Passage Bio discussed intracisternal magna administration of PBGM01.
Nilanjan Ghosh, MD, PhD, on Real-World Efficacy of CAR T-Cell Therapies
The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed data from real-world experience studies.
Steven W. Pipe, MD, on Challenges in Gene Therapy Trials for Hemophilia
The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed common challenges with gene therapy clinical trials.
Thomas Martin, MD, on Exciting Cell Therapy Options in Multiple Myeloma
The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed cilta-cel and upcoming cell therapies.
Massimo Trucco, MD, on the Potential of Islet Cell Transplant
The director of the Alleghany Health Network Institute of Cellular Therapeutics discussed possible applications of the procedure.
